All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 10, 2019
Home » Bearish investors no drag on biotech dealmaking
Looking to read the full article? Subscribe to BioWorld.
BIO-Europe 2019

Bearish investors no drag on biotech dealmaking

November 12, 2019
By Cormac Sheridan
No Comments
HAMBURG, Germany – Despite the biotech industry's recent record-breaking run in terms of fundraising and new drug approvals, the ongoing drug pricing controversy is acting as a drag on biotechnology investment. Since the debate started to heat up about four years ago, the Nasdaq Biotechnology Index is down 14%, while the S&P 500 Index is up by 46% during the same period, David Thomas, vice president, industry research at the Biotechnology Innovation Organization (BIO), told delegates attending the opening plenary session at BIO-Europe. "Something is clearly holding back investors in our space," he said.
BioWorld Europe Conferences

Already a subscriber? Sign in 

Popular Stories

  • Bioworld MedTech’s Oncology Extra

    BioWorld MedTech
    Keeping you up to date on recent developments in oncology.
  • Drugs-pills-global-map-

    Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

    BioWorld
    LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
  • Ear-disorders

    FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

    BioWorld MedTech
    The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
  • Frankyoung-11-27

    Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

    BioWorld
    Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
  • Biopharma companies continue their strong momentum in November

    BioWorld
    After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing